The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
EIA: Use at a concentration of 4 µg/ml.
RIA: Use at a concentration of 4 µg/ml.
WB: Use at an assay dependent dilution. Predicted molecular weight: 52 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.
Found in plasma.
Defects in SERPINC1 are the cause of antithrombin III deficiency (AT3D) [MIM:613118]. AT3D is an important risk factor for hereditary thrombophilia, a hemostatic disorder characterized by a tendency to recurrent thrombosis. AT3D is classified into 4 types. Type I: characterized by a 50% decrease in antigenic and functional levels. Type II: has defects affecting the thrombin-binding domain. Type III: alteration of the heparin-binding domain. Plasma AT-III antigen levels are normal in type II and III. Type IV: consists of miscellaneous group of unclassifiable mutations.
Belongs to the serpin family.
Phosphorylation sites are present in the extracelllular medium.
Hansen CB et al. The Levels of the Lectin Pathway Serine Protease MASP-1 and Its Complex Formation with C1 Inhibitor Are Linked to the Severity of Hereditary Angioedema. J Immunol195:3596-604 (2015).
Read more (PubMed: 26371246) »